Sanj K. Patel's most recent trade in Relay Therapeutics Inc was a trade of 1,450,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2026 | 1,450,000 | 1,450,000 | - | - | Stock Option (Right to Buy) | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.82 per share. | 06 Jan 2026 | 43,168 | 661,041 | - | 7.8 | 337,574 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.99 per share. | 06 Jan 2026 | 994 | 704,209 | - | 3.0 | 2,972 | Common Stock |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Nov 2025 | 111,794 | 111,794 (0%) | 0% | 0 | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Nov 2025 | 111,794 | 0 (0%) | 0% | 0 | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Nov 2025 | 60,000 | 51,794 (0%) | 0% | 0 | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Nov 2025 | 60,000 | 60,000 (0%) | 0% | 0 | Class A Ordinary Share | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.00 per share. | 03 Nov 2025 | 62,073 | 703,215 | - | 7 | 434,511 | Common Stock |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Oct 2025 | 121,248 | 136,721 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 20 Oct 2025 | 121,248 | 233,042 (1%) | 0% | 3.8 | 460,742 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 38.81 per share. | 20 Oct 2025 | 98,934 | 134,108 (0%) | 0% | 38.8 | 3,839,629 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Oct 2025 | 97,390 | 0 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 38.83 per share. | 20 Oct 2025 | 97,390 | 111,794 (0%) | 0% | 38.8 | 3,781,654 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 20 Oct 2025 | 97,390 | 209,184 (1%) | 0% | 3.8 | 370,082 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Oct 2025 | 39,331 | 97,390 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 38.77 per share. | 20 Oct 2025 | 39,331 | 111,794 (0%) | 0% | 38.8 | 1,524,863 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.80 per share. | 20 Oct 2025 | 39,331 | 151,125 (0%) | 0% | 3.8 | 149,458 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 39.32 per share. | 20 Oct 2025 | 22,314 | 111,794 (0%) | 0% | 39.3 | 877,386 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 137,638 | 137,638 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2025 | 34,435 | 34,435 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.49 per share. | 01 Sep 2025 | 10,983 | 108,402 (0%) | 0% | 33.5 | 367,821 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 9,992 | 119,385 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 9,992 | 9,991 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 6,569 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 6,569 | 114,971 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 6,481 | 12,962 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 6,481 | 109,393 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 6,238 | 18,712 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2025 | 6,238 | 102,912 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.28 per share. | 01 Sep 2025 | 3,177 | 111,794 (0%) | 0% | 34.3 | 108,908 | Class A Ordinary Share |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.57 per share. | 09 Jul 2025 | 42,740 | 783,927 | - | 3.6 | 152,582 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.57 per share. | 09 Jul 2025 | 18,639 | 765,288 | - | 3.6 | 66,541 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.94 per share. | 30 Jun 2025 | 5,000 | 826,667 | - | 2.9 | 14,700 | Common Stock |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 23 May 2025 | 62,116 | 158,790 (0%) | 0% | 1.6 | 98,764 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.33 per share. | 23 May 2025 | 62,116 | 96,674 (0%) | 0% | 27.3 | 1,697,630 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2025 | 62,116 | 0 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 23 May 2025 | 19,317 | 115,991 (0%) | 0% | 1.6 | 30,714 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.01 per share. | 23 May 2025 | 19,317 | 96,674 (0%) | 0% | 27.0 | 521,752 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2025 | 19,317 | 62,116 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 23 May 2025 | 4,837 | 101,511 (0%) | 0% | 1.6 | 7,691 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 23 May 2025 | 4,837 | 96,674 (0%) | 0% | 27 | 130,599 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2025 | 4,837 | 81,433 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2025 | 2,349 | 86,270 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 20 May 2025 | 2,349 | 99,023 (0%) | 0% | 1.6 | 3,735 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.02 per share. | 20 May 2025 | 2,349 | 96,674 (0%) | 0% | 27.0 | 63,470 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 13 May 2025 | 2,872 | 99,546 (0%) | 0% | 1.6 | 4,566 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 2,872 | 88,619 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.03 per share. | 13 May 2025 | 2,872 | 96,674 (0%) | 0% | 27.0 | 77,630 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.05 per share. | 07 May 2025 | 6,029 | 96,674 (0%) | 0% | 27.0 | 163,084 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 07 May 2025 | 6,029 | 102,703 (0%) | 0% | 1.6 | 9,586 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 6,029 | 91,491 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 07 May 2025 | 1,965 | 96,674 (0%) | 0% | 27 | 53,055 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 07 May 2025 | 1,965 | 98,639 (0%) | 0% | 1.6 | 3,124 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 1,965 | 97,621 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 27.00 per share. | 07 May 2025 | 101 | 96,674 (0%) | 0% | 27 | 2,727 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 07 May 2025 | 101 | 96,775 (0%) | 0% | 1.6 | 161 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 101 | 97,520 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 13,328 | 26,238 | - | - | Performance Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 12,910 | 12,910 | - | - | Performance Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 8,386 | 8,386 | - | - | Performance Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 7,987 | 7,987 | - | - | Performance Share Unit | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.97 per share. | 23 Apr 2025 | 42,769 | 840,320 | - | 3.0 | 127,024 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.97 per share. | 23 Apr 2025 | 18,653 | 821,667 | - | 3.0 | 55,399 | Common Stock |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 9,992 | 101,506 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 9,992 | 9,991 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.28 per share. | 07 Apr 2025 | 4,832 | 96,674 (0%) | 0% | 20.3 | 97,993 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 137,638 | 137,638 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 68,869 | 68,869 | - | - | Performance Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 34,435 | 34,435 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 6,481 | 90,597 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 6,481 | 12,962 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 6,238 | 96,835 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 6,238 | 18,712 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 3,017 | 91,514 (0%) | 0% | 21.8 | 65,680 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.77 per share. | 01 Apr 2025 | 2,304 | 94,531 (0%) | 0% | 21.8 | 50,158 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 6,569 | 0 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2025 | 6,569 | 86,120 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.61 per share. | 16 Mar 2025 | 2,004 | 84,116 (0%) | 0% | 22.6 | 45,310 | Class A Ordinary Share |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 332,465 | 958,413 | - | 0 | Common Stock | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.85 per share. | 11 Feb 2025 | 140,182 | 625,948 | - | 3.9 | 539,701 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.70 per share. | 11 Feb 2025 | 75,324 | 883,089 | - | 3.7 | 278,699 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.78 per share. | 21 Jan 2025 | 125,000 | 199,548 | - | 4.8 | 597,500 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.52 per share. | 21 Jan 2025 | 125,000 | 449,548 | - | 4.5 | 565,000 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 21 Jan 2025 | 125,000 | 324,548 | - | 4.8 | 600,000 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 1,105,000 | 1,105,000 | - | - | Stock Option (Right to Buy) | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 16 Dec 2024 | 100,000 | 574,548 | - | 5 | 500,000 | Common Stock |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 06 Nov 2024 | 89,561 | 79,551 (0%) | 0% | 23 | 2,059,903 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 89,561 | 10,025 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 06 Nov 2024 | 89,561 | 169,112 (0%) | 0% | 1.6 | 142,402 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 129,750 | 129,750 | - | - | Share Option | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 24,950 | 24,950 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 16,474 | 84,126 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 9,992 | 19,983 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 01 Sep 2024 | 7,967 | 76,159 (0%) | 0% | 26.7 | 213,038 | Class A Ordinary Share |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 6,569 | 82,728 (0%) | 0% | - | Class A Ordinary Share | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 6,569 | 6,569 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2024 | 6,482 | 19,443 | - | - | Restricted Share Unit | |
| Kiniksa Pharma Ltd (Class A) | Sanj K. Patel | Director, CHAIRMAN & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 01 Sep 2024 | 3,177 | 79,551 (0%) | 0% | 26.7 | 84,953 | Class A Ordinary Share |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.04 per share. | 25 Jul 2024 | 50,000 | 816,130 | - | 5.0 | 252,000 | Common Stock |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2024 | 50,000 | 518,779 | - | - | Stock Option (Right to Buy) | |
| Relay Therapeutics Inc | Sanjiv K. Patel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.16 per share. | 25 Jul 2024 | 50,000 | 766,130 | - | 9.2 | 458,000 | Common Stock |